These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18714171)

  • 41. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
    Kolodziej M; Neubauer MA; Rousey SR; Pluenneke RE; Perrine G; Mull S; Boehm KA; Ilegbodu D; Asmar L
    Clin Genitourin Cancer; 2006 Sep; 5(2):155-61. PubMed ID: 17026805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
    Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
    Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
    Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
    Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
    Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
    Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
    Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
    Ryan CJ; Rosenthal M; Ng S; Alumkal J; Picus J; Gravis G; Fizazi K; Forget F; Machiels JP; Srinivas S; Zhu M; Tang R; Oliner KS; Jiang Y; Loh E; Dubey S; Gerritsen WR
    Clin Cancer Res; 2013 Jan; 19(1):215-24. PubMed ID: 23136195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
    Small EJ; Fontana J; Tannir N; DiPaola RS; Wilding G; Rubin M; Iacona RB; Kabbinavar FF
    BJU Int; 2007 Oct; 100(4):765-9. PubMed ID: 17822457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
    Curigliano G; De Braud F; Teresa Sandri M; Renne G; Zorzino L; Scardino E; Rocco B; Spitaleri G; De Pas T; Noberasco C; Nolè F; Verweij F; Matei V; De Cobelli O
    Anticancer Drugs; 2007 Sep; 18(8):949-54. PubMed ID: 17667601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
    Osoba D; Tannock IF; Ernst DS; Neville AJ
    J Clin Oncol; 1999 Jun; 17(6):1654-63. PubMed ID: 10561201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
    Berry W; Dakhil S; Modiano M; Gregurich M; Asmar L
    J Urol; 2002 Dec; 168(6):2439-43. PubMed ID: 12441935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
    Nelson JB; Love W; Chin JL; Saad F; Schulman CC; Sleep DJ; Qian J; Steinberg J; Carducci M;
    Cancer; 2008 Nov; 113(9):2478-87. PubMed ID: 18785254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
    Yuasa T
    Int J Urol; 2009 Sep; 16(9):731-2. PubMed ID: 19769657
    [No Abstract]   [Full Text] [Related]  

  • 57. Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
    Birtle AJ; Newby JC; Harland SJ
    Br J Cancer; 2004 Oct; 91(8):1472-6. PubMed ID: 15381936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
    Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
    J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
    Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
    Lancet Oncol; 2007 Jul; 8(7):587-94. PubMed ID: 17544845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial.
    Manni A; Santen RJ; Boucher A; Lipton A; Harvey H; Simmonds M; White D; Gordon R; Ronher T; Drago J
    Anticancer Res; 1985; 5(2):161-5. PubMed ID: 3888046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.